Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04715399 · ClinicalTrials.gov registry record
UPenn Observational Research Repository on Neurodegenerative Disease
A clinical trial of Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (AD), sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT04715399: Recruiting study of Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (AD), sponsored by University of Pennsylvania.
NCT04715399 is a study of Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (AD) that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 1,000 participants, above the 247-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (305% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04715399, a study of Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (AD), is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
Primary Outcome
The changes of neuropsychological tests (well known cognitive measures such as: Naming test, CVLT, MoCA, Oral Trails, etc.) in neurodegenerative diseases over time.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-05-29 |
| Est. Completion | 2070-05-30 |
What NCT04715399 shows while recruiting
NCT04715399 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 247-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (305% higher).
The record links to 9 conditions, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT04715399 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04715399 about?
NCT04715399 is a clinical study titled "UPenn Observational Research Repository on Neurodegenerative Disease". The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
What is the current status of trial NCT04715399?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2020-05-29. Estimated completion is 2070-05-30.
What conditions does trial NCT04715399 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Primary Progressive Aphasia(PPA), Corticobasal Syndrome(CBS).
What interventions are being tested in trial NCT04715399?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04715399?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04715399 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04715399's enrollment target sits among peer trials
1,000 2nd of 18 higher than 16 of 18 other Amyotrophic Lateral Sclerosis (ALS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis (ALS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
-
Healing ALS Registry Observational Study (HAROS)
RECRUITING
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
RECRUITING · Phase 1
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
-
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI